- 期刊
Maviret於慢性C型肝炎病患之療效研究
A Study of the Effectiveness of Maviret in Patients with Chronic Hepatitis C Virus
摘要
目的：在台灣Maviret（Glecaprevir／Pibrentasvir）對慢性C型肝炎病患的實際療效與藥物使用評估數據是有限的，我們旨在評估在慢性C型肝炎患者中Maviret的臨床表現。方法：研究納入60例接受Maviret治療的慢性C型肝炎且無HCV相關性肝硬化代償性患者。：比較Maviret治療之前（基線）、8週治療結束（End of treatment, EOT）與結果在8週治療結束後12週（Follow-up 12）之持久性病毒反應（Sustained virologic response, SVR_(12)）和血液生化檢查。患者基線和EOT之間（p＜0.01）以及EOT和治療結束後的12週（p＜0.01）之間的GOT和GPT水平存在顯著差異。此外接受8週治療的患者的總體SVR率為100％。結論：患有慢性C型肝炎患者接受八週Maviret治療具有良好耐受性及導致較高的SVR_(12)。
並列摘要
Objective: The data regarding the realworld effectiveness and drug use evaluation of Maviret (glecaprevir / pibrentasvir) for patients with chronic hepatitis C virus (HCV) infection were limited in Taiwan. We aimed to evaluate the clinical performance of Maviret in HCV patient. Methods: A total of 60 patients with chronic hepatitis C without HCV-related compensated cirrhosis treated with Maviret were included in the study Results: Sustained virologic response at 12 weeks after the end of therapy (SVR_(12)) and the biochemical examinations were measured including before Maviret treatment (Baseline), at the end of treatment (EOT, 8 weeks), and at 12 weeks after EOT (Follow-up 12). The results revealed significant differences in GOT and GPT levels between Baseline and EOT ( p ＜ 0.01) and between EOT and Follow-up 12 ( p ＜ 0.01). The overall SVR_(12) rate was 100% in patients receiving 8 week of treatment. Conclusion: Maviret was well tolerated and a high SVR_(12) rate in treatment patients with chronic HCV infection was obtained.